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Mice transgenic for production of excessive or mutant forms of beta-amyloid diﬀer from patients with Alzheimer’s disease in
the degree of inflammation, oxidative damage, and alteration of intermediary metabolism, as well as the paucity or absence of
neuronal atrophy and cognitive impairment. Previous observers have suggested that diﬀerences in inflammatory response reflect a
discrepancy in the state of the locus coeruleus (LC), loss of which is an early change in Alzheimer’s disease but which is preserved
in the transgenic mice. In this paper, we extend these observations by examining the eﬀects of the LC on markers of oxidative
stress and intermediary metabolism. We compare four groups: wild-type or Tg2576 Aβ transgenic mice injected with DSP4 or
vehicle. Of greatest interest were metabolites diﬀerent between ablated and intact transgenics, but not between ablated and intact
wild-type animals. The Tg2576 DSP4 mice were distinguished from the other three groups by oxidative stress and altered energy
metabolism. These observations provide further support for the hypothesis that Tg2576 Aβ transgenic mice with this ablation may
be a more congruent model of Alzheimer’s disease than are transgenics with an intact LC.
1. Introduction
The degree of congruence between animal models and
human disease is likely to be a measure of how faithfully
preclinical compound validation will translate into eﬃcacy
in the clinic. Both academic and industrial laboratories
have made major investments in investigations of putative
disease-modifying treatments for Alzheimer’s disease, relying
on various mouse models transgenic for structural variants
or elevated quantities of beta-amyloid. Among them are
the Tg2576 mice which express the Swedish mutation of
APP (APPK670N, M671L) [1], which is the focus of this study.
This mutation causes increases in secreted Aβ1-40 and
Aβ1-42 [2, 3]. Although this and other transgenic models
reproducibly lead to pathological accumulations of beta-
amyloid, they poorly mimic several key pathologic features
of human Alzheimer’s disease: gross brain atrophy and
profound dementia [4]. This incongruence may compromise
their utility for validation for putative disease-modifying
treatments, particularly those directed not on amyloid
accumulation, but on downstream pathophysiology.
Several lines of evidence indicate that features other
than amyloid may also play critical roles in the patho-
logical cascade leading to the severe brain atrophy and
progressive dementia that are the ultimate clinical concern
in nonmendelian Senile Dementia of the Alzheimer Type
(SDAT), which in the last decade has come to be called
Alzheimer disease (AD), as it will be referred to in this
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paper. The most compelling come from two independent
prospective observational studies: the Religious Orders study
in Kentucky and the adjacent Midwest [5, 6] and the
similar, MRC Cognitive Function and Ageing Study (CFAS)
[7]. In both studies, subjects were assessed periodically for
cognitive ability and after death, their brains were examined.
In both studies, the relationship between amyloid burden
and cognitive impairment was complex. There were many
individuals whose total burden of amyloid pathology was
incongruent with their normal cognitive status, even when
all pathologies were considered in a multivariable model of
dementia risk factors. These observations suggested that a
congruent rodent model of AD also requires more than just
alterations of amyloid.
Although not understood completely, two biochemical
features of AD are oxidative damage [8–22] and inflamma-
tion [23]. Although these are prominent in AD, they are
variable in amyloid transgenic mice [24–29]. Another change
in human AD—but also absent or minor in transgenic
rodents—is early degeneration of the locus coeruleus (LC)
[30–41]. Work by Heneka et al. [42–45] suggested that
there may be a link between loss of the noradrenergic
LC and inflammatory changes in AD. The purpose of the
experiments described in this paper was to determine if there
is a similar link with oxidative stress and other metabolic
changes.
The LC is a midline brainstem nucleus that is the origin
of a widely projecting noradrenergic system, the major site
of norepinephrine synthesis in the brain that projects widely
to the neocortex and the hippocampus with terminals on
neurons, glia, and blood vessels [46]. Loss of noradrenergic
cells of the LC is an early event in human AD, comparable to
the more widely recognized loss of cells from the cholinergic
midline projection system originating in the substantia
innominata [40].
Heneka et al. [42] injected wild-type adult rats with
DSP4 [47, 48] to eliminate noradrenergic LC neurons and
then challenged with intracortical injections of Aβ. The
ablated rats showed greater induction of inflammatory
nitric oxide synthase, interleukin 1β, and IL-6 expression
in response to injection with Aβ than did control ani-
mals in which the LC had been left intact. This demon-
strated that LC loss in the rats augments inflammatory
responses to Aβ. In a followup study, APP23 transgenic mice
overexpressing Aβ were injected with DSP4 to selectively
destroy noradrenergic neurons in the LC as a model for
Alzheimer’s disease [45], with similar increases in inflam-
matory response. These observations invited our hypothesis
that LC loss in AD might be permissive not only for
increased inflammation but also for potentiation of oxidative
stress.
The specific goals of the current study were to determine
if the same ablative procedure of the LCwith DSP4 in Tg2576
mice would significantly alter other metabolic pathways that
are not aﬀected by transgenesis for amyloid in mice with an
intact LC and to determine if such alterations are typical of
human AD. Furthermore, we were interested in determining
only those metabolic changes resulting from this ablation
that were also dependent on transgenesis for amyloid and
were not simply nonspecific consequences of treatment with
DSP4 in control wild-type mice.
To ensure a comprehensive unbiased survey, we chose
to perform a metabolomic analysis. Metabolomics has
attracted increasing interest in the field of disease research,
since it has proven to be a fast and reproducible method
directly reflecting biological events. Metabolomics involves
the determination of changes in the levels of endogenous or
exogenous metabolites in biological samples, in response to
a perturbation such as disease, drug, or toxin. In the present
study, we used a combination of gas chromatography/mass
spectrometry (GC/MS) and liquid chromatography/mass
spectrometry (LC/MS) to monitor the biochemical changes
associated with a transgenic murine model system for
Alzheimer’s disease. This global metabolite profiling allows
the measurement of low molecular weight biochemicals
including lipids, sugars, nucleotides, organic acids, amino
acids, vitamins, cofactors, small peptides, and xenobiotics.
2. Materials and Methods
2.1. Neurochemical Analysis of Brain Tissue. DSP4 (50mg/kg
in PBS, N = 5) or PBS (vehicle, N = 5) was administered
intraperitoneally to C57BL/6SJL mice on days 1 and 7. Mice
were sacrificed 7 days following the second injection (day
14). Mice were euthanized by exposure to CO2 and the
brains removed. Frontal cortex tissue was dissected on ice
and frozen on dry ice for subsequent analysis of monoamine
concentration. Frozen tissue samples were weighed and
perchloric acid (0.4M) added at 10 μL/mg tissue. Samples
were made homogeneous using a sonicating probe. Samples
were then centrifuged at 15 000 rpm for 20min and the
supernatant removed. The supernatant was then centrifuged
in a filtered tube at 3000 rpm for 5min. This supernatant was
then diluted 1 in 100 for measurement of dopamine and 1
in 10 for measurement of DOPAC and HVA. Supernatant
was analyzed for neurochemical content using HPLC-ECD.
Chromatographic separations were performed using reverse
phase HPLC (C18 ODS3 column, 150× 3.0mm, Metachem,
Torrance, CA, USA). The mobile phase comprised: 0.15M
NaH2PO4, 0.25mM EDTA, 1.75mM 1-octane sulphonic
acid, 2% isopropanol and 4% methanol, pH = 4.6 and deliv-
ered at 0.5mL/min at 30◦C. Dopamine and metabolites were
detected using an electrochemical amperometric detector
(Decade, Antec-Leyden, NL) with a working electrode set at
+650mV versus Ag/AgCl reference electrode.
2.2. Preparation of Mice for Spectroscopic Analyses. A total of
120 samples from mice were used in this study, comprising
4 sets of 23 week old animals (n = 10/group): either
wild-type or Tg2576 Aβ transgenics which express the
Swedish mutation (APPK670N, M671L) of the amyloid protein
precursor (APP) [1]. Each 23 week-old animal was injected
intraperitoneally on day 1, (5 weeks prior to harvest) with
either vehicle (PBS) or DSP4 (N-(2-chloroethyl)-N-ethyl-2-
bromobenzylamine, Sigma C-8417), a selective neurotoxin
for noradrenergic neurons [47, 48] dissolved in PBS. Each
animal was injected intraperitoneally with a volume of
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5mL/kg. An identical injection was given to each animal 7
days later (on day 8) when animals were 24 weeks old. Four
weeks after the second injection, the mice were anesthetized
with 3% isoflurane and plasma, CSF, and brains (40 samples
each) were harvested for metabolite profiling, as described
below.
2.3. Sample Collection for Spectroscopic Analyses. Approxi-
mately 7 microliters of CSF was collected from each mouse
via the cisternamagna and visually inspected for the presence
of blood. Any sample that was contaminated with blood was
removed from the study. The collected CSF was immediately
frozen on dry ice. For the collection of plasma, the chest
cavity was opened and approximately 0.3mL of blood was
collected via cardiac puncture into EDTA tubes and the mice
were euthanized by exsanguination. The blood samples were
centrifuged to separate plasma. The plasma was collected and
immediately frozen on dry ice. Brains were extracted from
the skull and frozen on dry ice. For these brain samples, the
cerebellum was left intact.
The plasma (100 μL), CSF (approximately 7 μL) and
brain samples (half brain, 150mg) were extracted according
to Metabolon’s standard protocol, which uses a series of
proprietary solvent extractions designed to remove protein
and dislodge any small molecules bound to protein or physi-
cally trapped in the precipitated protein matrix. Each solvent
extraction step was performed by shaking for two minutes in
the presence of glass beads using a Glen Mills Genogrinder
2000. After each extraction the sample was centrifuged and
the supernatant removed using the MicroLab STAR robotics
system, followed by re-extraction of the pellet in subsequent
steps. The multiple extract supernatants were pooled and
then split into equal parts for analysis on the GC/MS and
LC/MS platforms. Further details on Metabolon’s extraction
procedures and metabolic profiling platform can be found in
Boudonck et al. [49, 50] and Evans et al. [51].
2.4. Data Collection and Quality Control. The data were
collected over two platform day runs each for plasma, CSF,
and brain matrix. Each day consisted of 19 or 20 study
samples, with samples from the diﬀerent treatment groups
equally distributed among the days, then randomized. Two
brain samples did not pass QC inspection and were omitted
from the study. Approximately 30% of process samples
were dedicated to QC. In addition to the study samples,
pooled samples of homogenized plasma, CSF, and brain
tissue were extracted four independent times per day. These
samples (CMTRX) served as technical replicates throughout
the data set to assess process variability. Also, 100 μL of
water was extracted five independent times per day to serve
as process blanks. Every sample analyzed was spiked with
standards tomonitor and evaluate instrument and extraction
performance [49].
2.5. Data Normalization. Raw area counts for each metabo-
lite in each sample were normalized to correct for variation
resulting from instrument interday tuning diﬀerences [49].
For each metabolite, the area counts were divided by its
median value for each run day, therefore setting the medians
equal to 1 for each day’s run. This correctly preserves all of
the variation between the samples yet allows metabolites of
widely diﬀerent raw peak areas to be compared directly on
a similar graphical scale. Missing values were assumed to
result from areas falling below the limits of detection. For
each metabolite, the missing values were imputed with the
observed minimum after the normalization step. Additional
normalization steps were added to correct for the volume
diﬀerences between samples in the diﬀerent matrices. For
plasma, several samples had volumes lower than 100 μL and
to those samples a correction factor was applied. For CSF,
sample volumes varied between 5 and 10 μL. Therefore, a
correction factor was applied to each sample based on the
total ion count for all metabolites present in the sample. For
brain samples a correction factor based on the total ion count
for all metabolites present in the sample was applied as well,
as in the case for CSF.
2.6. Statistical Analysis. Individual contrast analyses were
performed between various groups of the study. The
following comparisons were made: Tg2576 DSP4 versus
wild type DSP4, Tg2576 vehicle versus wild-type vehicle,
Tg2576 DSP4 versus Tg2576 vehicle, and wild-type DSP4
versus wild-type vehicle. In addition, a two-way (factorial)
ANOVA analysis was performed to test whether the mean
diﬀerence between genotype depends on the drug (or vice-
versa). Data were log-transformed for all tests. A conservative
P-value cutoﬀ of .01 was used for this study. To account for
multiple testing, false discovery rates (FDRs) were computed
for each comparison [52]. The FDRs were estimated using
the Q value method [53]. The Q value is a measure of
each metabolite’s significance that takes into account the
hundreds of comparisons that we are making simultaneously
in our analysis. The Q value, which is an extension of the
FDR, is similar to the more familiar P value, which is a
measure of the false positive rate. We use it in our univariate
analyses to minimize the occurrence of potentially mislead-
ing false positives that would be otherwise expected with the
performance of this many simultaneous comparisons.
2.7. Principal Component Analysis (PCA) and Partial Least
Squares-Discriminant Analysis (PLS-DA). Principal compo-
nents analysis (PCA) is a dimension reduction method
that uses a linear transformation of a sample of points to
exhibit the properties of the sample most clearly along the
coordinate axes [54]. This analysis is now routinely used in
the analysis of genome scale data sets, for example, [55].
The principal components (PCs) are displayed as a set of
“scores”, which highlight clustering or outliers, and a set of
“loadings”, which highlight the influence of input variables
on t. PCA and PLS-DA analysis were completed in SIMCA P
v12.0 (Umetrics AB) on a desktop PC running Windows XP
Professional with 3Gb RAM. For the PCA, a separate model
was built for each tissue; three models in total—one for
serum, one for CSF and one for brain tissue. The metabolite
intensity data was mean centered and scaled to unit variance
and the models were fitted using the autofit function. For
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Figure 1: Eﬀects of treatment with DSP4 on monoamine neuro-
transmitter levels. DSP4 (50mg/kg in PBS, N = 5) or PBS (vehicle,
N = 5) was administered intraperitoneally to C57BL/6SJL mice
on days 1 and 7. Mice were sacrificed 7 days following the second
injection (day 14). Brain was harvested and frontal cortex dissected
for analysis of monoamine concentrations, demonstrating a 68%
reduction of NE levels but no eﬀect on serotonin.
the brain samples, PLS-DAmodel was fitted using the autofit
function on mean centered unit variance scaled data.
3. Results
3.1. Eﬀect of DSP4 Pretreatment onMonoamine Levels in Brain
Tissue. Analyses of neurotransmitters in frontal cortices
dissected from C57BL/6SJL mice on day 14, after treatment
with DSP4 or vehicle on days 1 and 7, demonstrated a 68%
reduction in the levels of norepinephrine, but no detectable
eﬀect on levels of serotonin (Figure 1).
3.2. Platform QC and Study Precision. The quality control
data for this study can be summarized as follows: for plasma
samples, standards (n = 20) in CMTRX yielded a median
relative standard deviation (RSD) of 6.5%, nonstandards
(n = 326) in CMTRX yielded a median RSD of 17%; for CSF
samples, standards (n = 20) in CMTRX yielded a median
RSD of 6.5%, nonstandards (n = 68) in CMTRX yielded a
median RSD of 17%; for brain samples, standards (n = 20)
in CMTRX yielded a median RSD of 11%, nonstandards
(n = 194) in CMTRX yielded a median RSD of 23%.
Results of this analysis indicated that the platform performed
well within Metabolon’s QC specifications for both plasma
and CSF matrices. The brain RSD is higher because of the
significant presence of lipids in brain tissue.
3.3. Metabolite Summary. Full data curation of the plasma
samples yielded 487 chemical entities. 152 of these cor-
responded to identifiable chemical compounds and the
remaining represented currently unnamed compounds. The
CSF samples yielded 115 chemical entities, which is a
little less than is typically seen due to the smaller sample
volume of mouse CSF. 61 of these corresponded to identi-
fiable chemical compounds and the remaining represented
unnamed compounds. The brain tissue samples yielded 232
chemical entities. 115 of these corresponded to identifi-
able chemical compounds, and the remaining represented
unnamed compounds. Results for individual metabolites
are shown as Whisker plots demarcating upper and lower
quartiles and further annotated with mean and median
values.
3.4. Principal Component Analysis (PCA) and Partial Least
Squares-Discriminant Analysis (PLS-DA). For the plasma
specimens, autofit function generated a model containing
6 principal components that captured 56% of the total
variance. The principal components do not correspond with
experimental factors and the experimental groups do not
segregate clearly. For the CSF specimens, autofit function
generated a model containing 3 principal components
that captured 57% of the total variance. The scores plot
highlighted mouse Veh 11 as a potential outlier sample. The
principal components did not correspond with experimental
factors and the experimental groups did not clearly segregate.
In contrast, for the brain specimens, autofit generated a
model containing 7 principal components that captured 48%
of the total variance. The majority of principal components
did not correspond to a specific experimental factor but
a combination of PC3 and PC6 gave a separation of the
wild type and transgenic samples of brain metabolites. This
observation was confirmed using PLS-DA, using the wild
type and Tg2576 animals as groups. The Variable Importance
in Projection (VIP) plot highlighted the carbohydrate and
oxidative stress metabolites as the most significant in driving
the separation between the wild-type and Tg2576 data sets in
the PLS-DA analysis (Figure 2).
3.5. Overview of Biochemical Findings. Statistically signifi-
cant diﬀerences (P ≤ .05) were detected from amyloid
transgenesis alone (i.e., diﬀerences between transgenics and
the appropriate control group of wild-type animals, as
matched with respect to treatment with DSP4 or vehicle),
and from LC ablation alone (i.e., diﬀerences between DSP4-
treated animals and the appropriate control group of vehicle
animals, as matched with respect to transgenesis). How-
ever, of greatest interest were those changes that required
both amyloid transgenesis and also ablation of the LC,
that is, those in which Tg2576 DSP4 versus Tg2576 VEH
showed statistically significant changes but WT DSP4 versus
WT VEH did not. We will restrict the analysis in this paper
to those changes observed in the brain as a result of LC
ablation in Tg2576 transgenic animals, but not observed
in wild-type animals, at a more stringent P-value of ≤.01
(Table 1). In this latter group the major biochemical
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Figure 2: Principal components analysis. From an autofit model that yielded 7 principal components, a combination of PC3 and PC6 gives
a separation of the wild type and transgenic samples of brain metabolites. This figure shows the scores plot, derived by principal components
analysis, as a combination of Principal Component (PC) 3 on the x-axis and PC 6 on the y-axis. Each transgenic animal is represented by
a red circle, each wild type by a purple triangle. Each point is labeled either with VEH for vehicle treatment or DSP for drug treatment
followed by the number assigned to an individual mouse after assignment to a treatment group, but before any experimental procedure. The
clustering observed in this plot indicates separation of the wild-type and transgenic samples based on the global profile of all of the brain
metabolites detected in our analysis.
findings are: (1) The Tg2576 DSP4 mice already show
signs of oxidative stress at 28 weeks of age, as demon-
strated by decreased levels of several antioxidants such
as glutathione (Figure 3) and increases of oxidative stress
metabolite, ascorbate (Figure 4); (2) the Tg2576 DSP4 group
shows an overall decrease of carbohydrates in the gly-
colysis/gluconeogenesis and pentose phosphate pathways,
as well as minimal alterations of lactate, which varied
between the three tissue compartments (Figure 5). This is
consistent with decreased glucose turnover described in
the literature on AD; (3) changes in brain lipids, modest
increases in cholesterol and octadecanoic (stearic) acid
(Figure 6) in transgenics in which the LC was ablated,
in comparison to wild-type animals with the same LC
ablation.
3.6. Comparisons of Specific Biochemical Pathways
3.6.1. Oxidative Stress. Many small molecules involved in the
metabolism of glutathione, the major nonenzymatic cellular
antioxidant, showed significant changes in the brain tissue
of the Tg2576 DSP4 group (Figure 3 and Table 1). Of all the
metabolic comparisons performed in this study, the most
statistically significant is the decrease of oxidized glutathione
in brain tissue of lesioned transgenic mice (Tg2576 DSP4)
to that in wild-type mice with the same lesion (wt DSP4).
This comparison is significant at P-value of <.0005 and
a Q-value of 0.006. This appears to depend on both the
presence of amyloid and the absence of the LC inasmuch as
it is not seen in the comparison of wild-type animals with
transgenics in which the LC had been left intact. Comparison
of levels of oxidized glutathione in Tg2576 VEH to wt VEH
only yields diﬀerences with nonsignificant P = .536 and Q =
0.697. The same comparison with reduced glutathione in the
brain yields a P = .005, albeit with a marginal Q-value of
0.078. Similarly, this eﬀect also requires both amyloid and the
absence of the LC, since there is no diﬀerence in reduced glu-
tathione levels between wild-type and transgenic animals in
which the LC was left intact (P = .829, Q = 0.752) (Table 1).
There were also changes in the Tg2576 DSP4 brain levels
of all examined γ-glutamyl-peptides, which are produced
by γ-glutamyl transpeptidase- (GGT-) catalyzed cleavage
of γ-glutamyl residues from glutathione and transfer to
amino acids [56–59]. Of these, the most significant com-
parison is that of γ-glutamyl-leucine which is increased
in Tg2576 DSP4 brains to 1.23-fold the levels seen in
wt DSP4 brains, with P = .006 and Q = 0.081. As in the
case for oxidized and reduced glutathione, comparison of
transgenic and wild-type animals does not demonstrate a
diﬀerence in the presence of an intact LC (Table 1). Similar
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Table 1: The 10most statistically significant metabolic diﬀerences in brain tissue, associated with transgenesis for Tg2576 that were observed
after ablation of the locus coeruleus with DSP4 but not in animals in which the locus coeruleus had been left intact. The P-value describes
the false positive rate, the Q-value the false discovery rate.
Compound
Locus coeruleus ablated: Tg/wt Locus coeruleus intact: Tg/wt Tg-ablated/wt-ablated
(Ratio of means)
Tg-intact/wt-intact
(Ratio of means)P Q P Q
Glutathione, oxidized .000 0.006 .536 0.697 0.41 0.80
Glucose-6-phosphate .001 0.051 .121 0.458 0.78 0.88
D-arabitol .001 0.051 .193 0.505 0.69 1.12
Cholesterol .002 0.051 .853 0.752 1.51 0.95
Lactate .002 0.051 .135 0.461 0.84 1.06
Ascorbic acid .003 0.051 .251 0.530 0.73 0.92
Glutathione, reduced .005 0.078 .829 0.752 0.68 1.03
γ-glutamyl-leucine .006 0.081 .968 0.777 1.23 0.99
Octadecanoic acid .009 0.101 .058 0.423 1.12 1.07
Uric acid .010 0.101 .576 0.715 2.91 0.63
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Figure 3: Glutathione metabolism. Glutathione metabolism and gamma-glutamyl-dipeptide formation are altered in the brains of the
Tg2576 DSP4 group. For each metabolite, the distribution of values within each of the four cohorts is represented as a Whisker plot, with
the relative normalized intensity as the abscissa. Mean values represented by the black arrowheads, median values by blue arrowheads.
Detailed statistical comparisons of oxidized glutathione, reduced glutathione, and γ-glutamine-leucine are given in Table 1. Glutamic acid
was omitted from the table even though the P-value for the comparison of ablated transgenics to ablated wild-types was .0109, the Q-value
exceeded our threshold at a value of 0.154.
trends were seen for the other γ-glutamyl peptides, albeit
not at statistically significant levels (Figure 3). γ-glutamyl
transpeptidase- (GGT-) catalyzed cleavage plays important
roles in glutathione metabolism, amino acid transfer and
metabolism of toxic compounds [56–59]. Therefore, the
altered levels of γ-glutamyl dipeptides in the Tg2576 DSP4
group (Figure 3) are another indication of increased stress
conditions in this group.
Ascorbic acid levels (Figure 4) were severely reduced in
Tg2576 DSP4 brains (Table 1; P = .003, Q = 0.051) con-
sistent with reports that levels of ascorbate are altered in AD
[17]. As in the case of the glutathione pathway, there is no sig-
nificant diﬀerence in brain ascorbate levels in transgenic and
wild-type animals in which the LC remained intact (Table 1).
Paradoxically, there was an almost three-fold increase in
the uric acid level in the brains of the Tg2576 DSP4
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Figure 4: Ascorbic acid, another marker of oxidative stress. Box
plots for levels of ascorbic acid in the brain, displaying the
distribution of values within each of the four cohorts represented as
aWhisker plot, with the relative normalized intensity as the abscissa.
Mean values represented by the black arrowheads, median values
by blue arrowheads. Detailed statistical comparisons of ascorbate in
the four cohorts are given in Table 1.
group in comparison to the wt DSP4 group whereas the
amount of uric acid in the transgenic animals was 63%
that of wild type when the LC was left intact (Table 1).
In summary, the significant changes of antioxidants and
oxidative stress markers in the Tg2576 DSP4 group support
the model that transgenic Tg2576 mice, injected with DSP4,
show increased levels of oxidative stress as is seen in
AD.
3.6.2. Energy Metabolism. We observed an overall decrease
of carbohydrates involved in glycolysis, gluconeogenesis, and
the pentose phosphate pathway in Tg2576 DSP4 mice. The
most significant change was a decrease of the brain levels
of glucose-6-phosphate in Tg2576 DSP4 brains compared
to wt DSP4 brains (P = .001, Q = 0.051) (Table 1 and
Figure 5), a diﬀerence not observed between brains of unle-
sioned animals. Another possible indication of activation
of the pentose phosphate pathway is the equally significant
lowering of brain levels of D-arabitol, a naturally occurring
polyol with antioxidant properties that is synthesized in
the brain [57]. As is the case for the other antioxidant
metabolites described in earlier paragraphs, it is exclusively
altered in the brains of transgenic mice in whom the LC
has been lesioned (Tg2576 DSP4) with P = .001, Q =
0.051 (Table 1 and Figure 5). In the presence of an intact
LC, transgenic mice do not have a detectable diﬀerence in
brain levels of d-arabitol from wild-type mice. The third
significant alteration relating to energy metabolism in the
brains of Tg2576 DSP4 mice is a minimal decrease in lactate
levels (P = .002, Q = 0.051) (Table 1 and Figure 5).
Nearly all metabolites of the tricarboxylic acid (TCA)
cycle showed significant changes between wild-type and
Tg2576 transgenic mice, and between DSP4 and vehicle
mice. The TCA cycle intermediates are significantly increased
in Tg2576 vehicle mice compared to wild-type vehicle mice.
However, treatment with DSP4 reduced the TCA interme-
diates in both wild type and transgenic mice backgrounds.
Some TCA metabolites show rather minor changes in
the wild-type DSP4 versus wild-type VEH group, but a
significant change in the Tg2576 DSP4 versus Tg2576 VEH
comparison. The most statistically significant change was
for malic acid levels in the brains of Tg2576 DSP4 which
were shown to be minimally altered at 0.89-fold the level
in wt DSP4 brains, at a P = .032, Q = 0.212. However,
there was an even more significant alteration (P = .007,
Q = 0.206) comparing wild type and transgenic mice in
whom the LC was intact, albeit in the opposite direction.
In summary, the Tg2576 DSP4 mice showed reductions in
carbohydrates involved in the glycolysis, gluconeogenesis
and pentose phosphate pathways compared to wild type
controls.
3.6.3. Free Fatty Acids and Lipids. A diverse array of changes
in free fatty acids (FFA) and lipids were observed in this
study. However, only the change in octadecanoic (stearic)
acid was found to approach statistical significance (P = .009,
Q = 0.101) comparing Tg2576 DSP4 to wt DSP4 mice
(Table 1 and Figure 6). Brain cholesterol showed the same
trend. However, several other lipid-derived brain metabolites
showed a decrease in the Tg2576 DSP4 group compared to
the other treatment groups.
4. Discussion
The PCA analysis identified group diﬀerences between the
metabolic profiles in the brains of wild type and Tg2576
animals. These diﬀerences are subtle in that they are not
highlighted in the first principal components and the sum
of the variance of the principal components is only 11% of
the total variance. The PLS-DA analysis allows us to identify
the metabolites which contribute most to the separation of
the wild type and Tg2576 animal groups. These metabolites
are involved in carbohydrate metabolism and oxidative stress
response, which corresponds to the metabolites identified as
significantly diﬀerentially expressed in the univariate analysis
of the metabolite data. These changes also correspond with
known changes in the brain in AD where, it has been long
established that glucose metabolism is impaired in AD [12,
60]. The multivariate analysis of the metabolite data does
not reveal much significance over and above the univariate
analysis. With the exception of the genotype diﬀerences in
the brain samples, the other models fail to capture more
than 60% of the total variance. The majority of single or
pairs of principal components do not correspond to either
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Figure 5: Carbohydrate metabolism. Box plots demonstrating selective depressions in the brains of glucose-6-phosphate (an early
intermediary of anaerobic glycolysis as well as the pentose monophosphate shunt), lactate the end product of anaerobic glycolysis, and
D-arabitol, a polyol with antioxidant properties which is thought to be a product of the pentose phosphate pathway. For each metabolite, the
distribution of values within each of the four cohorts is represented as a Whisker plot, with the relative normalized intensity as the abscissa.
Mean values represented by the black arrowheads, median values by blue arrowheads. Detailed statistical comparisons of each of the pictured
metabolites in the four cohorts are given in Table 1.
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Figure 6: Lipids: Octadecanoic (stearic) acid and cholesterol. Box plots describing themodest elevations of octadecanoic acid and cholesterol
in the brains of transgenic animals in which the locus coeruleus had been ablated. For each metabolite, the distribution of values within each
of the four cohorts is represented as a Whisker plot, with the relative normalized intensity as the abscissa. Mean values represented by the
black arrowheads, median values by blue arrowheads. Detailed statistical comparisons of both of these metabolites in the four cohorts are
given in Table 1.
the drug or genotype experimental factors in the plasma or
the CSF. For this reason, we chose to limit this analysis to
the brain, even though multiple metabolites in plasma and
CSF did show apparently significant diﬀerences in individual
comparisons.
Mindful of the hazards attendant to multiple compar-
isons, we chose to focus on those brain metabolites that
demonstrated diﬀerences with a more restrictive nominal
P-value of ≤.01 (Table 1). In this set of 10 metabolites, six
fell eﬀectively within the conventional cutoﬀ value for False
Discovery Rate of Q ≤ 0.05 and the remaining four within
the range 0.05 < Q ≤ 0.10, indicating trends. Eight of these
10 most significantly altered metabolites relate to oxidative
stress.
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4.1. Oxidative Stress. The most significant change was in
the levels of glutathione, the major antioxidant protecting
cells from toxins such as free radicals. Glutathione is found
almost exclusively in its reduced form, since the enzyme
which reverts it from its oxidized form is constitutively active
and inducible upon oxidative stress. The severe depletion of
glutathione and its metabolites in the Tg2576 DSP4 brains
is consistent with the presence of increased oxidative stress
in these mice. This is an important finding since previous
studies examining the relationship between glutathione and
AD have been inconclusive [61, 62]. It is of interest that both
reduced and oxidized forms of glutathione were lowered,
indicating decreased synthesis or increased degradation.
Whatever the mechanism, these indicate a decreased capacity
to scavenge free radicals. Further support for the significance
of the observed diﬀerences in the glutathione cycle come
from the analysis of concordant trends in the γ-glutamyl
peptides, of which the alteration of γ-glutamyl-leucine
approached statistical significance (Table 1).
In addition to changes directly related to the glutathione
cycle, there was a statistically significant reduction of ascorbic
acid in the brains of transgenic animals in whom the LC
was ablated (P = .003, Q = 0.051) whereas no diﬀerence
was observed when the LC had been left intact (Table 1).
Reduced levels of ascorbate had been observed in AD [17].
Surprisingly, we also observed an apparently discordant
result in the elevation of uric acid levels in the brain of
Tg2756 DSP4mice, instead of the expected reduction, which
was observed in the unlesioned transgenics. Uric acid is a
scavenger of ROS, about as eﬀective as vitamin C. Tohgi
et al. [63] found that uric acid and xanthine are much
lower in AD CSF presumably because of impaired brain
metabolism. The increase of uric acid in our experimental
animals appears robust but unexplained. Similarly, there
were equivocal diﬀerences seen in levels of tocopherol.
Kontush and Schekatolina [64] have shown that vitamin E
levels in AD subjects vary widely depending on the study.
Furthermore, it is possible that some antioxidants show
significant changes in this study while others do not show the
same extent of changes because of only partial depletion of
norepinephrine (63%) or the relatively young age (23 weeks)
of the transgenic mice used in this study. Kawarabayashi et al.
[65] have previously shown that the accumulation of amyloid
β plaques in the Tg2576 mouse model only reach the levels
seen in AD brain between 15 and 23 months of age.
4.2. Energy Metabolism. Less direct but nevertheless com-
pelling evidence of increased oxidative stress in the brains
of Tg2756 DSP4 animals derives from our observations
of significantly altered levels of glucose-6-phosphate and
of the polyol D-arabitol (Table 1) [66–69]. Glucose-6-
phosphate can undergo a number of metabolic transfor-
mations. Besides being an intermediate in the Embden-
Meyerhof pathway, where it is reversibly isomerized to D-
fructose-6-phosphate by phosphoglucose isomerase, it can
also be irreversibly metabolized by NADP-linked glucose-6-
phosphate dehydrogenase in the first step of the oxidative
pentose phosphate pathway, or by phosphoglucomutase
in the first step of the glucuronic acid pathway [66].
Glucose-6-phosphate dehydrogenase plays a pivotal role in
homeostatic redox control by providing reducing equivalents
to glutathione. Thus, lower levels of glucose-6-phosphate
in the brains of transgenic animals in which the LC
has been ablated could indicate either decreased glucose
uptake or increased flux through the pentose monophos-
phate shunt, which has been shown to be induced in
AD [67], presumably to provide reductive compensation
to oxidative stress. Furthermore, the striking alteration
in the levels of D-arabitol, a little-studied polyol that is
believed to be derived from sugar phosphates in the pentose
monophosphate pathway, further supports alteration of this
pathway. However, the metabolic pathways for these and
other brain derived polyols have not yet been fully deter-
mined [68], so that our interpretation must be considered
speculative.
There is extensive literature documenting altered
metabolism of carbohydrates in AD [12, 60, 70]. Our claim
of greater concordance of LC-lesioned transgenic mice
with human AD is consistent with the general consensus in
the literature that glucose and carbohydrate metabolism,
and therefore the formation of cellular energy is reduced
severely in AD. Bigl et al. [71] observed a lowered glucose
metabolism in Tg2576 mice as well, but only at 24 months
of age were reductions in the key enzymes in the glycolysis
and gluconeogenesis pathway detected.
Several metabolites in the TCA cycle demonstrated an
interaction eﬀect between the genotype and drug (data
not shown), most notably malate. However, malate was
also significantly altered in comparisons of transgenics and
wild type animals in which the LC had been left intact.
TCA cycle proteins prone to reactive oxygen species (ROS)
damage include aconitase, pyruvate dehydrogenase and
alpha-ketoglutarate dehydrogenase, all of which have been
shown to be significantly reduced in AD [72–75].
4.3. Free Fatty Acids and Lipids. The remaining two of the ten
most statistically significant contrasts in the Tg2756 DSP4
brains relate to lipid metabolism, neither of which can
we relate readily to oxidative stress. There is a statistically
significant elevation in cholesterol in lesioned transgenic
animals, but no diﬀerence from wild-type in transgenic
animals with an intact LC (Table 1). The relationship of
cholesterol to autopsy findings in AD is complex, depending
on one’s use of the historical or the currently accepted
definition of AD. Up to this point in our discussion, we
have used the term AD exclusively to refer to sporadic, senile
onset Alzheimer’s disease, as it is referred to in the current
literature, but which had previously been referred to as SDAT,
Senile Dementia of the Alzheimer Type. This distinction is
germane to considerations of cholesterol metabolism. Two
independent autopsy studies have demonstrated a decrease
in cholesterol in the cerebral white matter in autopsies of
patients with Alzheimer’s disease as defined historically—
that is, autosomal dominant presenile dementia as described
by Alois Alzheimer [76]—in comparison with age-matched
controls or patients with SDAT. In contrast, cholesterol and
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certain other lipids were reduced in the frontal centrum
semiovale of patients with SDAT in comparison to age-
matched controls or patients with presenile dementia—
referred to by the authors of that report as “true Alzheimer’s
disease” [77]. It is of further interest that cholesterol loading
was found to modulate Aβ toxicity through depletion of
mitochondrial stores of glutathione, possibly furnishing
an indirect link to oxidative stress [78]. Be that as it
may, we cannot oﬀer a meaningful interpretation of this
statistically significant diﬀerence in cholesterol. Similarly, we
do not understand the modest elevation of octadecanoic
(stearic) acid in the brains of Tg2756 DSP4 mice, but note
its concordance with observations in autopsy studies of
Alzheimer’s disease [79] as well as to a report of its ability
to induce hyperphosphorylation of tau in an experimental
system [80].
5. Conclusion
This data provides further support to the original hypothesis
by Heneka et al. [42, 43], that loss of the widely projecting
noradrenergic LC is not just an incidental finding but may
contribute to key pathophysiological features of human
Alzheimer’s disease. Furthermore, it extends this hypothesis
from inflammation to oxidative stress and altered carbohy-
drate metabolism. It is an interesting historical note that after
an extensive body of work on the role of the noradrenergic
LC in Alzheimer’s disease [30–41, 81], most investigators
shifted their focus to the cholinergic substantia innominata,
in which cell loss is not as extensive [40]. Perhaps this
deserves reappraisal.
If the importance of the loss of the LC is corroborated
by studies of other markers of oxidative damage, such
as 8-hydroxyguanosine [82], 4-hydroxy-2-nonenal (HNE),
isoprostanes [83] and nitrotyrosine [84], this may have
practical consequences in the development of animal models
more congruent with the human disease. An important test
of this extended hypothesis will be comparison of cell loss
and cognitive function in amyloid transgenics in which the
LC has been ablated. If confirmed, not only would this have
practical consequences in the design of animal models, but
would also provide an experimental test of the hypothesis
that free radicals are the rate limiting step in this as well as
other neurodegenerative disorders [22].
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